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Neutralizing-antibody (nAb) is the major focus of most ongoing COVID-19 vaccine trials.
However, nAb response against SARS-CoV-2, when present, decays rapidly. Given the
myriad roles of antibodies in immune responses, it is possible that antibodies could also
mediate protection against SARS-CoV-2 via effector mechanisms such as antibody-depen-
dent cellular cytotoxicity (ADCC), which we sought to explore here.
Methods
Plasma of 3 uninfected controls and 20 subjects exposed to, or recovering from, SARS-
CoV-2 infection were collected from U.S. and sub-Saharan Africa. Immunofluorescence
assay was used to detect the presence of SARS-CoV-2 specific IgG antibodies in the
plasma samples. SARS-CoV-2 specific neutralizing capability of these plasmas was
assessed with SARS-CoV-2 spike pseudotyped virus. ADCC activity was assessed with a
calcein release assay.
Results
SARS-CoV-2 specific IgG antibodies were detected in all COVID-19 subjects studied. All
but three COVID-19 subjects contained nAb at high potency (>80% neutralization). Plasma
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from 19/20 of COVID-19 subjects also demonstrated strong ADCC activity against SARS-
CoV-2 spike glycoprotein, including two individuals without nAb against SARS-CoV-2.
Conclusion
Both neutralizing and non-neutralizing COVID-19 plasmas can mediate ADCC. Our findings
argue that evaluation of potential vaccines against SARS-CoV-2 should include investiga-
tion of the magnitude and durability of ADCC, in addition to nAb.
Introduction
The coronavirus disease of 2019 (COVID-19) pandemic is caused by the novel SARS-CoV-2
virus [1, 2]. According to the latest report from the Johns Hopkins Coronavirus Resource Cen-
ter, as of Feb 5, 2021, SARS-CoV-2 has infected >100 million individuals worldwide, and>26
million in the U.S. alone, leading to>450 thousand deaths [3]. With a wide variety of vaccine
candidates currently in various stages of clinical trials worldwide, it is important to consider
what vaccine correlates are likely to promote responses of sufficient magnitude and durability
to impart protection. Antibody responses develop against SARS-CoV-2 during the infection in
many subjects tend to increase over the course of disease and correlate with viral RNA titer
[4]. Neutralizing antibody (nAb) responses have been shown to preferentially target the recep-
tor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein (S), but the levels of nAb
were variable in infected subjects and can undergo fairly rapid decay kinetics [5, 6]. Other
non-RBD-specific Ab which target the SARS-CoV-2 S could be less apt to neutralization, but
nevertheless have important roles in viral control by coupling adaptive humoral responses to
natural killer (NK) cells through the mechanism of Ab-dependent cellular cytotoxicity
(ADCC).
Convalescent plasma has been used successfully against other infectious diseases such as
influenza and SARS and remains among the potential COVID-19 therapies producing efficacy
against COVID-19 in several small-scale studies [7–10]. Neutralization is considered a mecha-
nism of action for SARS-CoV-2 convalescent plasma. Additionally, other non-neutralizing
antibody-dependent effector mechanisms such as antibody-dependent cellular phagocytosis
(ADCP), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cyto-
toxicity (ADCC) have been shown to play a role in protection against other viruses [11–14].
For ADCC, NK cells recognize and bind to Ab opsonized (targeted) cells using their FcγRIII
receptor, CD16, leading to perforin and granzyme degranulation-mediated cytotoxicity of the
infected target cells. Since other humoral effector mechanisms have not been investigated for
efficacy in SARS-CoV-2 infection, we sought to explore whether ADCC was evident in plasma
from recovered or recovering COVID-19 patients in this study.
Materials and methods
Study cohort
This study comprised of 23 consenting subjects,�18 years of age and of both genders from
U.S. and Sub-Saharan Africa (SSA). The SSA samples included 2 plasma samples from con-
firmed COVID-19 individuals (SSA1 and SSA2), 1 COVID-19 exposed but unconfirmed by
SARS-CoV-2 RT-PCR individual (SSA3) and 3 pre-pandemic voluntary blood donor plasma
samples (N1, N2 and N3). The pre-pandemic samples were collected in SSA between March
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and May of 2019. Seventeen COVID-19 plasma samples (US1 to US17) were obtained from U.
S.. All COVID-19 diagnoses were determined by local health providers with RT-PCR of
SARS-CoV-2 in the buccal and/or nasopharyngeal swabs. All study procedures were approved
by the institutional review board at the University of Nebraska–Lincoln.
Cell lines
HEK-293T cells (CRL-3216, ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modi-
fied Eagle medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin–streptomy-
cin (P/S).
HEK-293T-hACE2 cells (HEK-293T cells expressing the human angiotensin-converting
enzyme 2) (NR-52511, BEI Resources, Manassas, VA, USA) were cultured in DMEM with
10% FBS and 1% P/S.
NK92.05-CD16-176V, a natural killer cell line engineered to express the high affinity
FcγRIII (generously provided by Dr. Kerry Campbell at Fox Chase Cancer Center) were main-
tained in αMEM complete media: MEM (M0644, Sigma, Burlington, MA, USA) supplemented
with 2.2g/L sodium bicarbonate (25080094, ThermoFisher Scientific, Waltham, MA), 0.1mM
2-mercaptoethanol (31350010, ThermoFisher Scientific, Waltham, MA), 2mM L-glutamine
(25005CI, Corning, NY, USA), 0.2mM myo-inositol (I5125, Sigma, Burlington, MA, USA),
0.02mM folic acid (F7876, Sigma, Burlington, MA, USA), 1% non-essential amino acids
(11140050, ThermoFisher Scientific, Waltham, MA), 1% sodium pyruvate (11360070, Ther-
moFisher Scientific, Waltham, MA), 1% P/S, 12.5% FBS, and 12.5% horse serum (H1138,
Sigma, Burlington, MA, USA). The cells were passaged every 4 days in the presence of 2.5–5%
freshly thawed J558L supernatant (see human IL-2 production).
J558L Hu-IL-2 cells, a mouse myeloma cell line that expresses human IL-2 (provided by Dr.
Kerry Campbell at Fox Chase Cancer Center) were cultured in RPMI media with 10% FBS, 1%
P/S, 2mM L-glutamine, 1% sodium pyruvate, 0.1mM 2-mercapotethanol, and 1% HEPES
(25060CI, ThermoFisher Scientific, Waltham, MA). All cells were maintained in 5% CO2 incu-
bator at 37˚C.
Human IL-2 production
J558L Hu-IL-2 cells were used to produce human IL-2 as a growth supplement for
NK92.05-CD16-176V cells. The cells were initiated in 10 ml culture media (see above) in a T25
flask. The day after thaw, the culture was transferred to a T75 flask and brought to a total vol-
ume of 30 ml. The cells were then expanded every 2–3 days until the desired volume was
achieved. The cells were allowed to grow for about one week, until the media turned yellow.
The culture was then centrifuged for 3 minutes at 1300 rpm. Supernatant was 0.22 μm filtered,
aliquoted and frozen at -80˚C.
Cells expressing SARS-CoV-2 spike and nucleocapsid proteins
Cells expressing either the SARS-CoV-2 spike or nucleocapsid proteins were generated for use
in the immunofluorescence assay (IFA) and as target cells in the ADCC assay. At 24-hours
before transfection, 8 x 105 HEK-293T cells per well were seeded into a 6-well plate with
DMEM, 20% FBS without P/S. The cells in each well were transfected with 2 μg of either
SARS-CoV-2 spike mammalian expression plasmid pcDNA3.1-SARS2-S (a gift from Dr. Fang
Li, 145032, Addgene, Watertown, MA, USA) [15] or SARS-CoV-2 nucleocapsid mammalian
expression plasmid pGBW-m4134903 (a gift from Ginkgo Bioworks, 151951, Addgene,
Watertown, MA, USA), using Fugene 6 (E2692, Promega, Madison, WI, USA) in Opti-MEM
PLOS ONE ADCC against SARS-CoV-2
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reduced serum medium (31985070, ThermoFisher Scientific, Waltham, MA). The transfected
cells were incubated at 37˚C in a 5% CO2 incubator for 48-hours.
Immunofluorescence assay (IFA) against SARS-CoV-2
To generate the microscopy slides for IFA, at 48-hours post-transfection, the transfected HEK-
293T cells expressing either the SARS-CoV-2 spike or nucleocapsid proteins were harvested
without trypsin, fixed with 4% PFA and seeded onto 12-well polytetrafluoroethylene (PTFE)
printed slides (6342505, Electron Microscopy Sciences, Hatfield, PA, USA). Each well con-
tained either mock, spike or nucleocapsid transfected cells. The cells were then permeabilized
with 0.3% H2O2 methanol solution, washed with 1X PBS, air-dried and stored at -80˚C. The
donor plasmas were first heat-inactivated at 56˚C for 1 hour, spun at 12,000 x g for 5 minutes
to remove any debris or aggregates, diluted at 1:20 with 1X PBS containing 0.1% Tween-20
and incubated at room temperature for 30 minutes. The IFA slides were thawed and incubated
with 1X PBS containing 0.1% Tween-20 for 30 minutes at 37˚C in a humidity chamber. Fifteen
microliters of the diluted plasmas were then added onto each well and incubated for 1 hour at
37˚C in a humidity chamber. After washing with 1X PBS, the secondary mouse monoclonal
anti-human IgG antibody (CRL-1786, ATCC, Manassas, VA, USA) was added and incubated
for 1 hour at 37˚C in a humidity chamber. After washings with 1X PBS, the slides were incu-
bated with the tertiary CY2 conjugated donkey anti-mouse IgG (715225150, Jackson Immu-
noResearch, West Grove, PA, USA) for 1 hour at 37˚C in a humidity chamber. Finally, the
slides were washed, stained with 0.004% Evans Blue solution for 30 seconds and washed to
remove excess staining solution. The slides were air-dried and protected by a cover slip with
Fluoromount Aqueous Mounting Medium (F4680, Sigma, Burlington, MA, USA). The slides
were examined by three independent readers using Nikon Eclipse 50i fluorescence micro-
scope. A sample was only considered positive if the results from at least two readers concurred.
Neutralization assay
SARS-CoV-2 spike glycoprotein pseudotyped lentivirus were generated by co-transfection of
HEK-293T cells with SARS-CoV-2 spike mammalian expression plasmid (pcDNA3.1-
SARS2-S, a gift from Dr. Fang Li, 145032, Addgene, Watertown, MA, USA) [15], 3rd genera-
tion lentiviral plasmid encoding EGFP (FUGW, a gift from Dr. David Baltimore, 14883,
Addgene, Watertown, MA, USA) [16] and the packaging plasmid (psPAX2, a gift from Dr.
Didier Trono, 12260, Addgene, Watertown, MA, USA). The culture supernatant containing
the pseudotyped virus was collected at 72-hours post-transfection and concentrated by
ultracentrifugation.
At 24-hours before the neutralization assay, 1 x 104 HEK-293T-hACE2 cells per well were
seeded into a 96-well plate. The donor plasmas were heat inactivated at 56˚C for 1 hour and
diluted at 1:40 with culture medium and 25 μl of the SARS-CoV-2 Spike pseudotyped virus for
a total volume of 200 μl per well. The plasma-virus mixtures were then incubated at 37˚C for 1
hour. The old culture medium of the pre-plated HEK-293T-hACE2 cells was then replaced
with the plasma-virus mixture, spun at 400 x g for 20 minutes and incubated at 37˚C in a 5%
CO2 incubator for 72 hours. The level of infection was determined by quantification of the
GFP signal using BD Accuri C6 Plus flow cytometer (BD Biosciences, San Jose, CA, USA) and
flow data analyzed by FlowJo software (BD Life Sciences, San Jose, CA, USA). Each plasma
sample was tested in triplicate. Each set of experiment contained mock-only cells and virus-
only cells. The percent GFP in mock cells was subtracted from all other samples, including
virus-only cells. To calculate the final percent neutralization, the following equation was used:
(Virus only–Sample)/Virus only x 100%. The data were then plotted and statistical analysis
PLOS ONE ADCC against SARS-CoV-2
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was conducted using GraphPad Prism version 5.05 (GraphPad Software, San Diego, CA,
USA).
Antibody-dependent cellular cytotoxicity (ADCC) assay
ADCC activity was assessed with a calcein release assay [17, 18]. Target cells (HEK-293T,
either mock transfected or expressing SARS-CoV-2 spike) were labeled with 2 μg/ml Calcein-
AM (C3099, ThermoFisher Scientific, Waltham, MA) at a concentration of 106 cells/ml for 30
minutes at 37˚C, 5% CO2. After labeling, excess dye was removed by washing the cells twice
with DMEM plus 10% FBS and cells were resuspended at a final concentration of 106 cells/ml.
The labeled target cells (105 cells) were aliquoted at 100 μl per well into a 96-well v-bottom
plate. Sample plasma at a final dilution of 1:50 (4 μl) were added to each experimental well and
allowed to incubate at room temperature for 15 minutes while the effector cells were prepared.
NK92.05-CD16-176V effector cells were resuspended at 5 x 106 cells/ml in αMEM complete
media and 100 μl (5 x 105 cells) were added to all wells, except the spontaneous and maximum
release control wells (Target cells only), for an effector to target ratio of 5:1. Maximum release
was achieved through the addition of 104 μl of 0.1% Triton-X-100, while 104 μl of αMEM
complete media were added to spontaneous release control wells. The 96-well v-bottom plate
was then spun at 100 x g for 2 minutes to increase cell interactions and incubated at 37˚C, 5%
CO2 for 4 hours. Following incubation, the wells were mixed via gentle pipetting, and spun at
400 x g for 2 minutes to pellet the cells and debris. The supernatant (150 μl) was transferred to
a black-walled 96-well clear bottom plate and fluorescence was determined with Victor3V
plate reader (PerkinElmer, Waltham, MA, USA).
Each plate contained the following controls: target cells only (spontaneous release); target
cells plus Trition-X-100 (maximum release); target cells and effectors, no plasma (TE). To cal-
culate the percent ADCC activity, this formula was used: [(Experimental-Spontaneous)—
(TE-Spontaneous)]/(Maximum-Spontaneous)�100%. Data is presented as the change in
ADCC (ΔADCC), where ADCC against mock is subtracted from ADCC against spike express-
ing cells (i.e. ADCC of spike–ADCC of mock). All samples were tested in quintuplicate and
data shown is the mean with standard deviation of the centroid three replicates. The data were
then plotted and statistical analysis (Mann Whitney) was performed using GraphPad Prism
version 5.05 (GraphPad Software, San Diego, CA, USA).
Results
To evaluate humoral neutralizing and ADCC responses against SARS-CoV-2 and to investi-
gate potential relationships between the two, we obtained plasmas from 18 confirmed
COVID-19 symptomatic individuals, 1 confirmed COVID-19 asymptomatic individual, 1 pre-
sumed highly exposed but asymptomatic SARS-CoV-2 seropositive individual and 3 SARS-
CoV-2 seronegative blood donors from the U.S. and sub-Saharan Africa (SSA) (Table 1).
Among the 17 U.S. COVID-19 samples, 5 individuals (US1, US2, US3, US16 and US17) had
recovered from COVID-19 when the plasma samples were collected. The remaining 12 U.S.
samples were individuals with severe COVID-19 infection that required hospitalization. Two
RT-PCR confirmed cases SSA1 and SSA2, symptomatic and asymptomatic, respectively, as
well as an exposed but non-RT-PCR confirmed seropositive individual (SSA3) (cohabitating
household member of SSA2 as well as a confirmed COVID-19 spouse) were from SSA. These
individuals all recovered from COVID-19. The three negative control cases (N1, N2 and N3)
were pre-pandemic healthy blood donors from SSA.
To determine if plasma from these COVID-19 cases contained SARS-CoV-2 specific IgG
antibodies, we developed an in-house immunofluorescence assay (IFA) using HEK293T cells
PLOS ONE ADCC against SARS-CoV-2
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expressing either SARS-CoV-2 S or nucleocapsid (N) proteins [19]. The assay detects binding
of SARS-CoV-2 specific IgG in the plasma to the viral proteins expressed in these cells. After
the addition of a secondary anti-human IgG antibody followed by a fluorescently tagged ter-
tiary antibody, SARS-CoV-2 positive plasma produced a green color in epifluorescence
microscopy (Fig 1). The expression of SARS-CoV-2 S and N proteins in HEK293T cells, 57.6%
and 58.4% respectively, were assessed via IFA with convalescent COVID-19 plasma. Using this
method, we detected strong IgG antibody responses against the SARS-CoV-2 S glycoprotein in
all COVID-19 individuals, and against the N protein in 18/20 COVID-19 individuals. Surpris-
ingly, COVID-19 individuals US13 and SSA3 only showed strong responses against the S gly-
coprotein, but no response against N. This result reinforces the concept that SSA3 was
sufficiently exposed to SARS-CoV-2 to generate an Ab response to a viral surface glycoprotein,
without generating a N protein response or exhibiting symptoms. No fluorescent staining
(green) was observed against SARS-CoV-2 S- and N- expressing cells by negative control plas-
mas. Likewise, no staining (green) was evident when SARS-CoV-2 plasma was applied to
mock transfected cells in parallel (Fig 1).
Since the detection of SARS-CoV-2 specific IgG does not guarantee the presence of neutral-
izing antibodies, we used a SARS-CoV-2 S-pseudotyped virus neutralization assay to evaluate
the presence of such antibodies. We detected significantly elevated neutralization at 84–97%
(p<0.05) in 17/20 COVID-19 plasmas compared to plasma from negative controls (Fig 2).
This finding is consistent with other studies showing nAb in the majority of COVID-19
Table 1. Study cohort information.
Sample ID Area of Origin Age Gender COVID-19 diagnosis by RT-PCR Symptomatic/Asymptomatic Disease Severity
US1 US 32 Male Confirmed Symptomatic Convalescent
US2 US 35 Male Confirmed Symptomatic Convalescent
US3 US 22 Female Confirmed Symptomatic Convalescent
US4 US 61 Female Confirmed Symptomatic Hospitalized
US5 US 76 Male Confirmed Symptomatic Hospitalized
US6 US 51 Female Confirmed Symptomatic Hospitalized
US7 US 60 Male Confirmed Symptomatic Hospitalized
US8 US 61 Female Confirmed Symptomatic Hospitalized
US9 US 81 Male Confirmed Symptomatic Hospitalized
US10 US 79 Male Confirmed Symptomatic Hospitalized
US11 US 72 Male Confirmed Symptomatic Hospitalized
US12 US 59 Male Confirmed Symptomatic Hospitalized
US13 US 76 Female Confirmed Symptomatic Hospitalized
US14 US 79 Female Confirmed Symptomatic Hospitalized
US15 US 85 Male Confirmed Symptomatic Hospitalized
US16 US 31 Female Confirmed Symptomatic Convalescent
US17 US 59 Female Confirmed Symptomatic Convalescent
SSA1 SSA 26 Male Confirmed Symptomatic Mild
SSA2 SSA 31 Female Confirmed Asymptomatic N/A
SSA3 SSA 32 Male N/A Asymptomatic N/A
�N1 to N3 SSA N/A N/A N/A N/A N/A
“�” denotes pre-pandemic negative control plasmas.
“US” denotes United States of America.
“SSA” denotes sub-Saharan Africa.
N/A denotes not-applicable or not-available.
https://doi.org/10.1371/journal.pone.0247640.t001
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infected individuals [20]. It was surprising, however, that there was no significant nAb activity
in the plasma from COVID-19 individuals US4, US15 and SSA3, despite the fact that they had
detectable anti-S glycoprotein antibodies. It is possible that at the time of sample collection
these individuals were in early stages of infection and had experienced insufficient time or
viremia to develop detectable levels of nAb. In addition, these individuals may have other fac-
tors that weaken their humoral responses. Given that SSA3 remained asymptomatic despite
two sources of household exposure, it is also plausible that T-cell responses, or alternatively,
non-neutralizing Ab effector responses, such as ADCC (targeted against the S glycoprotein),
may have provided protection against symptomatic COVID-19.
To test for non-neutralizing responses, we performed a calcein-release ADCC assay with
NK92.05-CD16-176V effector cells to measure SARS-CoV-2 specific responses against mock-
transfected cells and cells expressing S protein (Fig 3). Target cells for ADCC were produced
by transfecting HEK-293T cells with mammalian CMV-promoter SARS-CoV-2 S expression
plasmid and 57.6% of the cells express the S protein after transfection as shown in Fig 1. The
target cells were then labeled with non-fluorescent Calcein-AM, a dye that is intracellularly
converted to green fluorescent calcein. The NK92.05-CD16-176V effector cells will recognized
these dye-labeled and Ab decorated antigen expressing target cells via its FcγRIII receptor that
binds to the Fc region of the bound antibody. This recognition activates the NK cell which
then disrupts the plasma membrane of target cells and release calcein into the culture superna-
tant, where it was quantified by a fluorescent plate reader. We found that plasma in 19/20
SARS-CoV-2 infected/exposed individuals induced ADCC activity against S glycoprotein-
expressing targets (Fig 3A) that was significantly higher (P = 0.0011) compared to negative
Fig 1. Immunofluorescence assay (IFA) against SARS-CoV-2 proteins. Representative pictures of IFA against either the mock, SARS-CoV-2 spike or
nucleocapsid expressing HEK-293T cells. The upper row shows IFA with negative control plasma collected before the COVID-19 pandemic. The lower row
shows IFA with COVID-19 plasma, where strong green color positive cells (indicated by white arrows) were only observed in cells expressing either
SARS-CoV-2 spike or nucleocapsid proteins. The lack of green color positive cells with negative control plasma and mock cells demonstrated the specificity of
the IFA. All pictures were taken at 20X magnification with Nikon Eclipse 50i fluorescence microscope. The white scale bars indicate 50 μm.
https://doi.org/10.1371/journal.pone.0247640.g001
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controls (Fig 3B). All individuals with nAb also demonstrated ADCC activity. Of the three
individuals without nAb, sample US4 was the only individual who had SARS-CoV-2 spike spe-
cific antibodies that were non-neutralizing and unable to induce ADCC activity. The reason
for the absence of ADCC activity in US4 is not clear, even though there are antibodies that
bind to both spike and nucleocapsid proteins. One possible explanation is the lack of anti-
SARS-CoV-2 antibody subclasses that can bind the FcγRIII receptor with high affinity to
mediate ADCC in our assay [21]. The remaining two individuals, US15 and SSA3 had SARS-
CoV-2 spike specific antibodies as detected by IFA but lacked nAb. Yet, their plasma was still
able to induce significant ADCC activity against the S-expressing target cells, strongly indicat-
ing that non-neutralizing antibodies might play a role against SARS-CoV-2 via ADCC.
Discussion
Our study demonstrated that specific SARS-CoV-2 S glycoprotein targeting antibodies from
COVID-19 plasma can induce ADCC killing via NK cells in-vitro. Although speculation as to
the presence of ADCC against SARS-CoV-2 has been reported, there has been little direct
experimental evidence [22, 23]. Several studies showed human and murine mAb against
SARS-CoV displayed cross-reactive ADCC responses against SARS-CoV-2, but no study has
Fig 2. SARS-CoV-2 spike pseudotyped virus neutralization assay. SARS-CoV-2 spike pseudotyped lentivirus virus encoding EGFP were
tested against negative control pre-pandemic plasmas (N1, N2 and N3) and COVID-19 plasmas (US1 to US17 and SSA1 to SSA3) at 1:40
plasma dilution. At 72-hours post-infection, percentage of GFP positive cells were quantified with BD Accuri C6 Plus flow cytometer. The
mean of triplicate wells was shown with error bars representing SEM. P-values were calculated via one-way ANOVA and “�” denotes
p< 0.05 relative to negative control plasmas.
https://doi.org/10.1371/journal.pone.0247640.g002
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examined COVID-19 plasma for its capacity to directly mediate ADCC [24, 25]. Despite our
findings and those in previous reports, whether SARS-CoV-2 specific ADCC actually occurs
in-vivo, will require further investigation with a larger sample size and functional testing of NK
Fig 3. Antibody-dependent cellular cytotoxicity (ADCC) assay. The ADCC activity of COVID-19 plasmas were
tested against HEK-293T cells expressing SARS-CoV-2 spike protein, which served as the target cells. After incubation
with plasma, Calcein-AM labeled target cells were incubated with NK cells (NK92.05-CD16-176V) which served as the
effector cells. The amount of fluorescent calcein released into the medium was then measured with Victor3V plate
reader. A) changes in ADCC (ΔADCC) activity against the spike protein, relative to their respective activity against
mock cells. N denotes pre-pandemic negative control plasmas. US and SSA denotes COVID-19 samples from USA and
sub-Saharan Africa, respectively. B) Comparison of ΔADCC against the spike protein between COVID-19 and
negative control plasmas. P-values were calculated via Mann Whitney test.
https://doi.org/10.1371/journal.pone.0247640.g003
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cells from the infected individuals in conjunction with autologous plasma. Several studies have
suggested dysfunction and decreased number of NK cells in patients with severe COVID-19
disease, which may undermine the role that NK cells and ADCC play in disease recovery [26,
27]. Nevertheless, ADCC may still be an important factor in vaccine efficacy. Moreover, in
addition to NK cells, other FcγRIII receptor-expressing cells, such as macrophages, neutro-
phils, and eosinophils, could also mediate ADCC. The detection of ADCC inducing-antibodies
in COVID-19 individuals also supports the exploration of other antibody-dependent effector
mechanisms, such as ADCP and CDC, and their role in COVID-19 pathogenesis and
recovery.
The major implication of our findings is that efficacy of COVID-19 vaccine candidates
should not be evaluated solely based on the level of nAb elicited, but rather the totality of
SARS-CoV-2 specific humoral responses elicited. The potential contributions and durability
of non-neutralizing antibody effector mechanisms need to be included in such assessments.
Therefore, in addition to T-cell responses, a qualitative examination of other immune cells
such as NK cells and macrophages should also be taken into consideration. Clearly, given the
importance and urgency of developing an effective COVID-19 vaccine, a larger more in-depth
study will be warranted to dissect the role of non-neutralizing Ab more completely in COVID-
19 patients and vaccinated individuals.
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